Search Results - e

1435 Results

Sort By:

First in class Small Molecule Agonists of the mammalian Relaxin family receptor 1 (RXFP1) and use in treatment of cancer, fibrotic, and vascular disorders (HHS Ref No. E-145-2024-0-US-02)

It is well documented in literature that activation of RXFP1 by relaxin induces: 1) up-regulation of the endothelin system which leads to vasodilation; 2) extracellular matrix remodeling through regulation of collagen deposition, cell invasiveness, proliferation, and overall tissue homeostasis; 3) a moderation of inflammation by reducing levels of inflammatory...

Published: 5/30/2025 | Inventor(s): Juan Marugan, Mark Henderson, Kenneth Wilson, Wenwei Huang, Wenjuan Ye, Noel Southall, Jiankang Jiang, Khalida Shamim, Bing Li, Alexander Agoulnik, Abhijeet Kapoor, Joshua Hutcheson, Ana Cabrera, Irina Agoulnik

Keywords(s):

Category(s): Application > Therapeutics, Application > Research Materials, TherapeuticArea > Oncology, TherapeuticArea > Cardiology, TherapeuticArea > Pulmonology, TherapeuticArea > Dermatology, TherapeuticArea > Reproductive Health, TherapeuticArea > Geriatrics

Antibodies to TMC1 Protein for Hearing Loss

This technology includes antibodies for TMC1 protein as a treatment for hearing loss. TMC1 is one of the common genes causing hereditary hearing loss. Our laboratory used synthetic peptides corresponding to the TMC1 protein to immunize rabbits. The resulting antisera were shown to bind to TMC1 protein expressed in heterologous expression systems. TMC1...

Published: 5/19/2025 | Inventor(s): Andrew Griffith, Tomoko Makishima, Valentina Labay

Keywords(s):

Category(s): Application > Research Materials, Application > Therapeutics, ResearchProducts > Antibodies, Collaboration Sought > Licensing, Collaboration Sought > Materials Available

Next-Generation 5-HT-2B Serotonin-Receptor Antagonists for Anti-Fibrotic & Cardiopulmonary Therapy

This technology includes a family of small-molecule antagonists that selectively block the 5-HT2B serotonin receptor—an upstream driver of tissue-remodeling—to address fibrotic, cardiopulmonary and related disorders. Built on a conformationally-locked “(N)-methanocarba” nucleoside scaffold, the compounds show nanomolar potency,...

Published: 5/14/2025 | Inventor(s): Kenneth Jacobson, Dilip Tosh

Keywords(s):

Category(s): Application > Research Materials, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Cardiology, TherapeuticArea > Dermatology, TherapeuticArea > Immunology, TherapeuticArea > Metabolic Disease, TherapeuticArea > Oncology, TherapeuticArea > Pulmonology, TherapeuticArea > Respiratory

Nanobody–Antiviral Peptide Conjugates for Potent HIV Entry Inhibition

This technology includes a new class of nanobody–antiviral peptide conjugates that block HIV from infecting human CD4⁺ T-cells, positioning them for future therapeutic and prophylactic use. Nanobodies—single-domain antibody fragments—guide the drug to the virus’s docking site and impede receptor binding, while the linked peptide...

Published: 5/14/2025 | Inventor(s): Ross Cheloha, Shubhra Saha

Keywords(s):

Category(s): Application > Research Materials, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease, TherapeuticArea > Reproductive Health

PET Imaging Agents for Fungal Infections

Available for licensing and commercial development are patent rights covering PET imaging agents, methods of their synthesis, and their uses in imaging specific fungal infections. Fungal infections remain a global health problem resulting in over 1.5 million annual deaths. Immunocompromised patients, especially those undergoing cancer treatments or...

Published: 5/9/2025 | Inventor(s): Dima Hammoud, Swati Shah, Peter Williamson, Rolf Swenson, Xiang Zhang, Falguni Bhattacharyya

Keywords(s):

Category(s): Collaboration Sought > Collaboration, Application > Diagnostics, Collaboration Sought > Licensing

Broadly neutralizing influenza hemagglutinin stem-directed antibodies

In 2023, the World Health Organization (WHO) reported roughly 3 to 5 million cases of severe influenza worldwide, resulting in approximately 290,000 to 650,000 deaths. Given the high disease burden, the needs for both prophylactic and therapeutic influenza strategies remain significant. However, current treatments for influenza are susceptible to resistance...

Published: 5/8/2025 | Inventor(s): Sarah Andrews, Grace Mantus, Ankita Chopde, Adrian Creanga, Rebecca Gillespie, Masaru Kanekiyo, Julie Raab

Keywords(s):

Category(s): Application, Application > Therapeutics, Application > Vaccines, Collaboration Sought, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Collaboration Sought > Materials Available, ResearchProducts > Antibodies, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology

A Novel Strategy to Produce 6-cys Proteins Based on Pfs230D1 Domain Fusions

The Plasmodium parasite has a complex lifecycle during human infection and in the mosquito vector. Most advanced malaria vaccine candidates can confer only partial, short-term protection in malaria-endemic areas. A means of breaking the transmission of malaria to subsequent individuals could prevent a significant amount of human disease. The primary...

Published: 5/8/2025 | Inventor(s): Patrick Duffy, Jonathan Renn

Keywords(s):

Category(s): Application, Application > Research Materials, Application > Therapeutics, Application > Vaccines, Collaboration Sought, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, ResearchProducts > Sequences, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease

Francisella Lipids as Broad Anti-inflammatory Therapeutics

Anti-inflammatory treatments, particularly those used in the context of viral infection, have been shown to greatly inhibit the overall immune response, which can result in poor immunity and failure to control or clear the infection. Novel alternatives that can effectively attenuate inflammation without the more serious side effects of steroid medications...

Published: 5/13/2025 | Inventor(s): Catharine Bosio, Glenn Nardone, Robin Ireland

Keywords(s):

Category(s): Application, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, TherapeuticArea > Immunology

Fluorophthalimides as Anti-inflammatory Agents for Systemic and Neurodegenerative Disorder

Summary: The National Institute on Aging (NIA) seeks research co-development partners and/or licensees for the pre-clinical and clinical development of the compounds as anti-inflammatory therapeutics for systemic and neurodegenerative disorders. Description of Technology: Numerous systemic, as well as neurological disorders, have a hallmark inflammatory...

Published: 6/5/2025 | Inventor(s): Nigel Greig, Weiming Luo, David Tweedie, Michael Scerba, Daniela Lecca, Shih Chang Hsueh

Keywords(s):

Category(s): TherapeuticArea > Neurology, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics

4-Amino-2-(piperidin-3-yl)isoindoline-1,3-diones as Anti-inflammatory Agents for Systemic Degenerative and Neurodegenerative Disorders

Summary: The National Institute on Aging (NIA) seeks research co-development partners and/or licensees for the pre-clinical and clinical development of the compounds as anti-inflammatory therapeutics for systemic degenerative and neurodegenerative disorders. Description of Technology: The immunomodulatory imide drugs (IMiDs) thalidomide and its close...

Published: 5/2/2025 | Inventor(s): Nigel Greig, Michael Scerba, David Tweedie

Keywords(s):

Category(s): TherapeuticArea > Geriatrics, TherapeuticArea > Neurology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing

1 2 3 4 5 6 7 8 9 10 ...